FDA - Spark Newswire

2 minute read

FDA
News

Virios Therapeutics Reports First Patient Dosed In P hase 2b Trial Evaluating IMC-1 In Patients with Fibromyalgia

Today, 7:56 PM

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses,

VIRI

2 minute read

FDA
News

Imara To Present Clinical Data On IMR-687 In Sickle Cell Disease At European Hematology Association Congress Jun. 15 At 10 a.m. EDT

By Benzinga Newsdesk

Today, 7:56 PM

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m.

IMRA

1 minute read

FDA
News

Surface Oncology Reports Collaboration With Roche To Evaluate Co.’s Investigational Anti-IL-27 Antibody In Combo With Roche’s Atezolizumab, Bevacizumab In Patients With Treatment-Naïve Hepatocellular Carcinoma

By Benzinga Newsdesk

Today, 7:56 PM

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche

SURF

3 minute read

FDA
News

BeyondSpring Reports First Patient Dosed In Triple-Combo Study With Plinabulin, PD-1/PD-L1 Inhibitor, Radiotherapy For Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

By Benzinga Newsdesk

Today, 7:56 PM

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed

BYSI

6 minute read

FDA
News

Fate Therapeutics Reports Interim Data From Phase 1 Study Of FT516 In Combo With Rituximab For B-Cell Lymphoma At American Society Of Clinical Oncology

By Benzinga Newsdesk

Today, 7:56 PM

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable

FATE

3 minute read

FDA
News

AstraZeneca Reports IMFINZI Showed Survival In Unresectable Stage 3 Lung Cancer With 43% Of Patients Surviving 5 Years

By Benzinga Newsdesk

Today, 7:56 PM

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting WILMINGTON,

AZN

1 minute read

UPDATE: UK’s Medicines and Healthcare products Regulatory Agency Says Data For Neutralizing Antibodies Of Pfizer/BioNTech’s COVID-19 Vaccine Work At Same Levels As Seen In Adults Aged 16-25 Years

By Benzinga Newsdesk

Today, 7:56 PM

-Reuters

BNTX

1 minute read

UK’s Medicines and Healthcare products Regulatory Agency Concludes Positive Safety Profile For Pfizer/BioNTech’s COVID-19 Vaccine In 12-to-15 Year Olds

By Benzinga Newsdesk

Today, 7:56 PM

-Reuters-Reuters

BNTX

1 minute read

Medtronic Pulls Plug On Heart Implant Device Amid Growing Concerns Over Patient Safety

By Kate White

Today, 7:56 PM

Medtronic PLC (NYSE: MDT) announced Thursday that it is stopping the distribution and sale of the Medtronic HVAD System, an implantable heart pump, after numerous data indicated higher occurrences of adverse events, including stroke and mortality, as compared to other circulatory-support devices.

MDT

3 minute read

FDA
News

Novartis Says Co Reports Clinically Relevant Improvement In Median Overall Survival Data In Final Analysis Of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera

By Benzinga Newsdesk

Today, 7:56 PM

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR

NVS